Loading
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
Previous close
$48.54
−$1.35 · -2.71%
Pre-market
$48.84
+$0.30 · +0.62%
Sep 9, 8:16 AM ET
Regular session · ET · Market data may be delayed.
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
Day range
Current $48.54
52-week range
Current $48.54
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
98
Deep Value
Sentiment
54
Mixed
Risk
23
Moderate Risk
Momentum
48
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
Day range
Current $48.54
52-week range
Current $48.54
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (GBP) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 32.67B GBP | 31.38B GBP | 30.33B GBP | 29.32B GBP | 24.7B GBP |
| Cost of goods sold | 9.02B GBP | 9.05B GBP | 8.57B GBP | 9.55B GBP | 8.16B GBP |
| Gross profit | 23.65B GBP | 22.33B GBP | 21.76B GBP | 19.77B GBP | 16.53B GBP |
| Research and development | 7.53B GBP | 6.4B GBP | 6.22B GBP | 5.49B GBP | 5.02B GBP |
| Selling, general, and administrative | 9.09B GBP | 11.02B GBP | 9.39B GBP | 8.37B GBP | 7.07B GBP |
| Operating expenses | 15.31B GBP | 18.31B GBP | 15.02B GBP | 13.34B GBP | 12.18B GBP |
| Interest income | 56M GBP | 67.39M GBP | 40M GBP | 64.27M GBP | 28M GBP |
| Interest expense | 687M GBP | 657.58M GBP | 775M GBP | 855.53M GBP | 784M GBP |
| Depreciation and amortization | 2.31B GBP | 2.55B GBP | 2.29B GBP | 2.15B GBP | 2.12B GBP |
| Operating income | 8.34B GBP | 4.02B GBP | 6.75B GBP | 6.43B GBP | 4.36B GBP |
| Net income | 5.72B GBP | 2.58B GBP | 4.93B GBP | 14.96B GBP | 4.39B GBP |
Company facts updated Sep 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Cash distributions grouped by calendar year; partial years are marked.
$1.6985
2025 complete year-26.8% since 2021
2026 partial: $1.3841
$2.3202
2,021
$1.6812
2,022
$1.3904
2,023
$1.557
2,024
$1.6985
2,025
$1.3841
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Aug 14, 2026 | $0.4515Quarterly | Aug 14, 2026 | Oct 8, 2026 |
Dividend | May 15, 2026 | $0.455Quarterly | May 15, 2026 | Jul 9, 2026 |
Dividend | Feb 20, 2026 | $0.4776Quarterly | Feb 20, 2026 | Apr 9, 2026 |
Dividend | Nov 14, 2025 | $0.4331Quarterly | Nov 14, 2025 | Jan 8, 2026 |
Dividend | Aug 15, 2025 | $0.43Quarterly | Aug 15, 2025 | Oct 9, 2025 |
Dividend | May 16, 2025 | $0.4348Quarterly | May 16, 2025 | Jul 10, 2025 |
Ex-dividend Aug 14, 2026
$0.4515
Quarterly
Record Aug 14, 2026 · Payment Oct 8, 2026
Ex-dividend May 15, 2026
$0.455
Quarterly
Record May 15, 2026 · Payment Jul 9, 2026
Ex-dividend Feb 20, 2026
$0.4776
Quarterly
Record Feb 20, 2026 · Payment Apr 9, 2026
Ex-dividend Nov 14, 2025
$0.4331
Quarterly
Record Nov 14, 2025 · Payment Jan 8, 2026
Ex-dividend Aug 15, 2025
$0.43
Quarterly
Record Aug 15, 2025 · Payment Oct 9, 2025
Ex-dividend May 16, 2025
$0.4348
Quarterly
Record May 16, 2025 · Payment Jul 10, 2025
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR Portfolio Developed World ex-US ETFSPDW122.81M0.29%42.46B USD0.03%$52.08-0.44%
Avantis International Equity ETFAVDE70.52M0.36%19.18B USD0.23%$93.69-0.87%
Fidelity Enhanced International ETFFENI56.79M0.49%11.47B USD0.28%$41.35-0.77%
VanEck Pharmaceutical ETFPPH42.28M4.03%1.01B USD0.36%$110.43-3.31%
First Trust Value Line Dividend Index FundFVD33M0.41%8.13B USD0.62%$49.69-0.86%
GMO International Value ETFGMOI15.7M2.20%699M USD0.60%$41.52-0.69%
Hartford Multifactor Developed Markets (ex-US) ETFRODM14.8M0.81%1.82B USD0.29%$42.19-0.94%
Avantis International Large Cap Value ETFAVIV10.58M0.50%2.1B USD0.25%$83.04-0.72%State Street SPDR Portfolio Developed World ex-US ETFSPDWAvantis International Equity ETFAVDEFidelity Enhanced International ETFFENIVanEck Pharmaceutical ETFPPHFirst Trust Value Line Dividend Index FundFVDGMO International Value ETFGMOIHartford Multifactor Developed Markets (ex-US) ETFRODMAvantis International Large Cap Value ETFAVIVAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
